Evogene (NASDAQ:EVGN) Now Covered by StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Evogene (NASDAQ:EVGN) in a research report issued on Sunday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Evogene Price Performance

NASDAQ EVGN opened at $1.46 on Friday. Evogene has a 12 month low of $1.20 and a 12 month high of $10.40. The firm has a market capitalization of $7.83 million, a PE ratio of -0.33 and a beta of 1.29. The company’s 50 day simple moving average is $1.59 and its 200 day simple moving average is $2.16.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Evogene stock. Citadel Advisors LLC purchased a new position in Evogene Ltd. (NASDAQ:EVGN) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 15,891 shares of the biotechnology company’s stock, valued at approximately $30,000. Citadel Advisors LLC owned about 0.30% of Evogene as of its most recent filing with the Securities & Exchange Commission. 10.40% of the stock is currently owned by institutional investors.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.